Physician profile
Isaac Gorbaty
NPI 1477562718
$412.81
in general payments reported to CMS, 2019-2025
14 companies · $73.18 in 2025
The $73.18 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.31 · 2021: $28.74 · 2023: $127 · 2024: $167 · 2025: $73.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329 · Education: $38.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.57 |
| Education | $38.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.02 | 2023-2025 | |
| Pfizer INC. | $42.39 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $40.13 | 2023 | Rexulti |
| Madrigal Pharmaceuticals | $36.94 | 2024 | Resmetirom |
| Travere Therapeutics, INC. | $32.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $28.60 | 2024 | Airsupra |
| Amgen INC. | $28.30 | 2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $26.57 | 2024 | |
| Lundbeck LLC | $24.89 | 2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $18.92 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Exact Sciences Corporation | $15.04 | 2023 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Gorbaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.